Seagen: Brentuximab Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Sponsor: Seagen

Double blinded study investigating the efficacy of Brentuximab Vedotin in conjunction with Rituximab and Lenalidomide to treat patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL).